Tristan Brittain-Dissont

SpringHill Management Ltd. (SpringHill) is a private equity fund management firm specializing in the field of life sciences, focusing upon early-stage investments and development capital. Located in Guildford, SpringHill was founded by Dr. Kim Tan.

Sphere Medical Ltd. develops monitoring and diagnostic products to provide clinical and economic benefits in critical care environment. It offers microfabricated and transducers technologies. The company was founded in March 2002 by Gavin Troughton and is headquartered in Cambridge, the United Kingdom.

E-Synergy Ltd. (E-Synergy) is a private equity and venture capital firm founded in 1999 by Stevenson Andrew and Armstrong Ronald Akers. The firm headquartered in London, United Kingdom.

Psimei Pharmaceuticals Ltd. develops pharmaceutical products. It provides radiation therapy and treatment of cancer cells using a technique called Photon Activation Therapy. The company is headquartered in Bramley, the United Kingdom.

Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development.